• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Chermaine Lee

Articles by Chermaine Lee

Iceland's Alvotech partners with China's Changchun to develop biosimilars

Oct. 3, 2018
By Chermaine Lee
Alvotech ehf., of Iceland, and an independent sister company of U.S. pharmaceutical firm Alvogen Group Inc., recently joined hands with China's Changchun High & New Technology Industries Group Inc. to develop, manufacture and commercialize Alvotech's biosimilars in the Asian country. The collaboration will see a new joint venture with manufacturing capabilities in China's Jilin province, which will be equally funded by both companies.
Read More

Amgen's Blincyto enters Asia market via approval for ALL patients in Japan

Oct. 3, 2018
By Chermaine Lee
HONG KONG – Japan's Ministry of Health, Labour and Welfare gave the nod to Blincyto (blinatumomab) for use in relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), marking the bispecific T-cell engager's entry into the Asian market, following approvals in the U.S., all members of the EU and European Economic Area, Canada and Australia.
Read More

Increasing globalization in biopharma highlights differing management styles, cultures

Oct. 3, 2018
By Chermaine Lee
HONG KONG – The recent M&A deal between Japan's 237-year-old Takeda Pharmaceutical Co. Ltd. and Irish firm Shire plc has attracted massive attention, not just because of the mammoth size of the deal but also the tug of war among the Japanese company's shareholders, a group of which made a failed attempt to block the deal during Takeda's general meeting earlier this year.
Read More

Iceland's Alvotech partners with China's Changchun to develop biosimilars

Oct. 2, 2018
By Chermaine Lee
Alvotech ehf., of Iceland, and an independent sister company of U.S. pharmaceutical firm Alvogen Group Inc., recently joined hands with China's Changchun High & New Technology Industries Group Inc. to develop, manufacture and commercialize Alvotech's biosimilars in the Asian country. The collaboration will see a new joint venture with manufacturing capabilities in China's Jilin province, which will be equally funded by both companies.
Read More

Amgen's Blincyto enters Asia market via approval for ALL patients in Japan

Oct. 1, 2018
By Chermaine Lee
HONG KONG – Japan's Ministry of Health, Labour and Welfare gave the nod to Blincyto (blinatumomab) for use in relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), marking the bispecific T-cell engager's entry into the Asian market, following approvals in the U.S., all members of the EU and European Economic Area, Canada and Australia.
Read More

Increasing globalization in biopharma highlights differing management styles, cultures

Sep. 28, 2018
By Chermaine Lee
HONG KONG – The recent M&A deal between Japan's 237-year-old Takeda Pharmaceutical Co. Ltd. and Irish firm Shire plc has attracted massive attention, not just because of the mammoth size of the deal but also the tug of war among the Japanese company's shareholders, a group of which made a failed attempt to block the deal during Takeda's general meeting earlier this year. (See BioWorld, May 8, 2018.)
Read More

Hisun plans China filing after HS-25 hits LDL-C phase III goals

Sep. 26, 2018
By Chermaine Lee
HONG KONG – China's Zhejiang Hisun Pharmaceutical Co. Ltd. said results of two key phase III trials for HS-25, a cholesterol absorption inhibitor that targets hyperlipoproteinemia, showed both met the standard 12-week descent rate of low-density lipoprotein cholesterol (LDL-C), while adverse drug reactions were minor. In the next one to two months, the company is expected to apply to the National Medical Products Administration (NMPA), China's FDA, for marketing clearance.
Read More

Hisun plans China filing after HS-25 hits LDL-C phase III goals; faces generic statins

Sep. 21, 2018
By Chermaine Lee
HONG KONG – China's Zhejiang Hisun Pharmaceutical Co. Ltd. said results of two key phase III trials for HS-25, a cholesterol absorption inhibitor that targets hyperlipoproteinemia, showed both met the standard 12-week descent rate of low-density lipoprotein cholesterol (LDL-C), while adverse drug reactions were minor. In the next one to two months, the company is expected to apply to the National Medical Products Administration (NMPA), China's FDA, for marketing clearance.
Read More

Streamlined process speeds Fosun Kite's CAR T drug to clinic

Sep. 19, 2018
By Elise Mak and Chermaine Lee
HONG KONG – Shanghai-based Fosun Kite Biotechnology Co. Ltd. was granted approval from China's National Medical Products Administration (NMPA) to advance its gene therapy candidate, FKC-876, to clinical trials.
Read More

Faster green light for imported drugs ignites international biopharmas' interest in China

Sep. 18, 2018
By Elise Mak and Chermaine Lee
HONG KONG – China has seen a busy month of drug approvals, from Lenvima (lenvatinib, Eisai Co. Ltd. and Merck & Co. Inc.) on Sept. 5 to Elunate (fruquintinib, Hutchison China Meditech Ltd.) and Soliris (eculizumab, Alexion Pharmaceuticals Inc.) on Sept. 6. More notably, the three drugs, all accepted under the priority review pathway, were granted marketing approval in about a year.
Read More
Previous 1 2 3 4 5 6 7 8 9 10 11 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 11, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 8, 2025
  • 3D rendering of a molecular glue mediating the interaction between two proteins

    With surface mimicry, molecular glues shed hairpin need

    BioWorld Science
    Degradation is a therapeutic strategy that could offer possibilities to get at currently undruggable target proteins. In targeted degradation, compounds induce...
  • Incurix describes new c-Myc inhibitors

    BioWorld Science
    Incurix Co. Ltd. has identified Myc proto-oncogene protein (c-Myc) inhibitors reported to be useful for the treatment of cancer.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe